A central theme of the call was the company’s sampling-first approach. Schimmelpennink said the strategy is designed to let patients try the eye drop before purchase, creating “natural self-selection” in which those who experience benefit and choose to buy may be more likely to continue therapy. Management contrasted this with a dynamic it described for Vuity, where patients often had to purchase before trying, potentially contributing to a faster early ramp but also a subsequent drop-off.On persistence, ex ...

Lenz Therapeutics (NASDAQ: LENZ) stock tumbled 11.2% through 9:50 a.m. ET Tuesday after missing on Q4 earnings. Heading into the report, analysts forecast Lenz to lose $0.90 per share on quarterly sales of $3.1 million. Lenz lost $1.16 per share on sales of only $1.6 million. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: ...

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -28.18%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.59, delivering a surprise of +11.94%.Over the last four quarters, the company ...

LENZ Therapeutics (NasdaqGS:LENZ) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsAlyssa Larios - Research AssociateDan Chevallard - CFOEvert Schimmelpennink - President and CEOMelanie Gloria - Equity Research AssociateShawn Olsson - Chief Commercial OfficerConference Call ParticipantsBrian Abrahams - Senior Research AnalystLachlan Hanbury-Brown - Equity Research AnalystMatthew Caufield - Director and Senior Biotechnology Equity Research AnalystStacy Ku - Biotech AnalystYigal Nochomovit ...

LENZ Therapeutics (NasdaqGS:LENZ) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsAlyssa Larios - Research AssociateDan Chevallard - CFOEvert Schimmelpennink - President and CEOMelanie Gloria - Equity Research AssociateShawn Olsson - Chief Commercial OfficerConference Call ParticipantsBrian Abrahams - Senior Research AnalystLachlan Hanbury-Brown - Equity Research AnalystMatthew Caufield - Director and Senior Biotechnology Equity Research AnalystStacy Ku - Biotech AnalystYigal Nochomovit ...

LENZ Therapeutics (NasdaqGS:LENZ) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Speaker1Good morning, and thank you for joining us today. My name is Dan Chevallard, Chief Financial Officer of LENZ Therapeutics. We are joined today by Evert Schimmelpennink, our President and Chief Executive Officer, and Shawn Olsson, our Chief Commercial Officer, as well as Dr. Marc Odrich, Chief Medical Officer, who will join us for the question-and-answer session. Before we begin, I would like to remind you that this ca ...

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment ...

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights. ...

Core Viewpoint - Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics by 48.9% during the third quarter, indicating a potential shift in investment strategy or confidence in the company [2] Institutional Investment Activity - Versant Venture Management LLC acquired a new stake in LENZ Therapeutics valued at approximately $123.76 million during the third quarter [3] - Adage Capital Partners GP L.L.C. increased its stake by 108.8% in the second quarter, now holding 1,122,738 shares worth $32.91 million after acquiring an additional 585,000 shares [3] - Franklin Resources Inc. raised its position by 6,756.1% in the third quarter, owning 587,084 shares valued at $27.35 million after acquiring 578,521 shares [3] - UBS Group AG increased its stake by 36.3% in the third quarter, now owning 1,201,616 shares valued at $55.97 million after acquiring 320,135 shares [3] - Hedge funds and institutional investors collectively own 54.32% of LENZ Therapeutics [3] Analyst Ratings - HC Wainwright maintained a "buy" rating for LENZ Therapeutics [4] - Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Zacks Research downgraded the stock from "strong-buy" to "hold" [4] - Weiss Ratings reiterated a "sell (d-)" rating [4] - William Blair reissued an "outperform" rating [4] - The consensus rating for LENZ Therapeutics is "Moderate Buy" with a price target of $56.40 [4] Stock Performance - LENZ Therapeutics opened at $12.15, with a market cap of $380.17 million [5] - The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $25.99 [5] - The one-year low for the stock is $11.21, while the one-year high is $50.40 [5] - The company has a P/E ratio of -5.76 and a beta of 0.52 [5] Company Overview - LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to improve vision in the U.S. [6] - Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for treating presbyopia [6]

Summary of LENZ Therapeutics Conference Call Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Product**: Eye drop for treating presbyopia, named VIZZ - **Launch Timeline**: Product approved in August and launched in October 2025 Industry Context - **Market Size**: Approximately 120 million presbyopes in the U.S. [18] - **Competitive Landscape**: - LENZ is the only company with aceclidine as an active ingredient - Competitors include AbbVie's VUITY (pilocarpine-based) and Qlosi (low-dose pilocarpine), both of which have shown limited efficacy [12][13] - VUITY had a 25% effectiveness rate, with only 1 in 4 patients noticing an effect [12] - VUITY's sales force has significantly reduced, indicating market struggles [13] Product Efficacy - **Mechanism of Action**: Aceclidine stimulates the iris sphincter to create a smaller pupil, enhancing near vision without affecting distance vision [9][10] - **Clinical Trial Results**: - 71% of patients experienced significant near vision improvement after 10 hours of use [8] - The product is designed to provide near vision improvement for the majority of the day [8] Launch Insights - **Initial Feedback**: Positive reception from both doctors and patients, with high awareness and willingness to prescribe [30][31] - **Refill Rates**: Early indications show encouraging refill rates, suggesting product stickiness [29] - **Sampling Strategy**: A robust sampling strategy is in place, allowing patients to try the product before committing to a prescription [29][40] Sales and Marketing Strategy - **Sales Force Expansion**: Plans to increase the sales force to 117 representatives to enhance market penetration [34] - **Target Audience**: 80% of prescriptions are written by optometrists, with the remaining 20% by ophthalmologists [46] - **Geographic Focus**: Strong sales in states like Florida, California, New York, and Texas [49] Safety and Side Effects - **Adverse Events**: Minimal reports of side effects such as headaches, redness, or dimness, with most effects being short-lived [85][90] - **Retinal Issues**: LENZ has reported only one case of retinal tear, compared to 34 reported by VUITY, indicating a safer profile [91][96] Market Expectations - **Sales Projections**: Consensus estimates for quarterly sales are around $2 million, with annual projections between $35-$40 million [129][130] - **Investor Sentiment**: There is impatience in the investment community regarding script data, but the company emphasizes the importance of building a market and establishing a solid foundation [168][170] Future Plans - **Direct-to-Consumer Campaign**: A DTC campaign has been initiated to increase awareness and drive prescriptions, with early signs of increased web traffic and interest [146][148] - **International Expansion**: The company is pursuing partnerships for international commercialization, with recent filings in Europe [173] Conclusion - LENZ Therapeutics is positioned uniquely in the presbyopia market with a product that shows promising efficacy and safety. The company is focused on expanding its market presence through strategic sales efforts and marketing campaigns while addressing investor concerns about growth and market penetration.